Advertisement

Expert Point of View: Tracy Rose, MD, MPH


Advertisement
Get Permission

Tracy Rose, MD, MPH

Tracy Rose, MD, MPH

THE FORMAL DISCUSSANT of the KEYNOTE-427 trial, Tracy Rose, MD, MPH, of the University of North Carolina, Chapel Hill, told listeners: “I think pembrolizumab should now be considered an option for non–clear cell kidney cancer. Response rates, however, remain inferior to those seen in clear cell kidney cancers. We really need randomized studies to know what to do. Programmed cell death ligand 1 staining as well as subtype may be predictive of response, although I do not think we can use either to dictate therapy at this point,” she added.

Dr. Rose noted that the disease control rate was 33% in the chromophobe subtype. “This is a histology that has been historically difficult to treat and unresponsive to our available treatments,” she commented. “Sunitinib is currently the standard of care for non–clear cell renal cell carcinoma, but it’s very clear that pembrolizumab is better tolerated than sunitinib in the first-line setting,” she added. 

DISCLOSURE: Dr. Rose has received research funding from Genentech/Roche, X4P Pharmaceuticals, and GeneCentric Therapeutics.


Related Articles

KEYNOTE-427: Pembrolizumab Shows Activity in Advanced Non–Clear Cell Kidney Cancer

IMMUNOTHERAPY WITH the checkpoint inhibitor pembrolizumab may prove to be an effective option for patients with advanced non–clear cell renal cell carcinoma, according to results in cohort B of the KEYNOTE-427 trial, presented at the 2019 Genitourinary Cancers Symposium.1 Kidney cancers with a...

Advertisement

Advertisement



Advertisement